Navigation Links
Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
Date:12/11/2008

CARY, N.C., Dec. 11 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on developing and commercializing prescription medications for respiratory disorders, today provided an update on the status of its integration activities following the closing of the business combination of Critical Therapeutics, Inc. and Cornerstone BioPharma Holdings, Inc. on October 31, 2008, and the renaming of the combined company as Cornerstone Therapeutics Inc. (the Company).

Following the October 31, 2008 closing, the Company has been taking action to effectively and efficiently combine the operations of the two companies. In completing the integration, the Company has achieved a number of key milestones:

  • The Company has discontinued all former Critical Therapeutics research projects and completed a review of those research projects to identify promising technologies suitable for outlicensing to third parties. As a result of this review, the Company has initiated a process to seek potential licensees for certain technologies, including the alpha 7 mediated anti-inflammatory pathway program.
  • The Company completed a restructuring of former Critical Therapeutics officers and employees that resulted in Scott Townsend, General Counsel and Executive Vice President of Legal Affairs, and 12 former Critical Therapeutics sales representatives remaining with Cornerstone.
  • The former Critical Therapeutics facility in Lexington, MA has been vacated and the sublease terminated.

Aggregate revenues from the Company's products have continued to be strong in the fourth quarter. The Company anticipates 2008 net revenues to be in excess of $64 million, which will include revenues attributable to ZYFL
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013 BioConvergence team ... speaking faculty at 2013’s BioLogistics Summit in San ... coordinated by Cold Chain IQ and IQPC, addressed ... “complexity” is, in part, attributed to current trends ... “Implicit within these trends is an increase in ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased to publish ... sulfur in ultra-low sulfur diesel (ULSD) using the new ... . The analysis detailed in Rigaku Application Note 1272 ... International Standard specifies an energy dispersive X-ray fluorescence (EDXRF) ... automotive gasoline. , Regulations around the world have limited ...
(Date:6/19/2013)... MN (PRWEB) June 19, 2013 Express ... abuse tests, today announced that it has received Class ... market and sell its DrugCheck® NxStep Onsite Drug ... use of the rapid screening device in near-patient settings, ... Drug Screen Cup received Health Canada Class III approval ...
(Date:6/18/2013)... 2013 Tabletop SEMs are inexpensive and ... have limited performance and capability such as small sample ... would normally provide better imaging performance and more analytical ... have a higher cost of maintenance. The Pemtron ... these two types of SEM product, offering competitive prices ...
Breaking Biology Technology:BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3
... U.S. Food and Drug Administration clears new implant for ... Innovations, Inc. (SBi),a single-source provider of products, technology and ... orthopedic industry, announced that its,Artelon(R) STT Spacer has been ... This product extends SBi,s line of surgically implanted, ...
... FRAZER, Pa., Sept. 21 Cephalon, Inc. (Nasdaq:,CEPH) ... Drug Application (NDA) to,the U.S. Food and Drug ... the treatment of patients with chronic,lymphocytic leukemia (CLL). ... disease with an estimated 15,000 new cases diagnosed ...
... CLARA, California, September 21, ChemAxon, a software solutions ... A ) today announced an,agreement to maintain the ... ChemAxon,s software suite. Agilent acquired,the Kalabie ELN from ... between Klee and ChemAxon to Agilent and ChemAxon. ...
Cached Biology Technology:Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 2Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 3Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 4Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis 5Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 2Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 4ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook 2
(Date:6/19/2013)... specifically for human consumption qualifies as a gluten-free cereal ... (CD), scientists have confirmed in a study published in ... , Joyce Irene Boye and colleagues point out ... States alone have CD. They develop gastrointestinal and other ... that contain gluten-related proteins. Boye,s team sought to expand ...
(Date:6/19/2013)... NEW YORK , June 19, 2013  New ... #8,461,981 by the United States Patent and Trademark Office ... security systems that reflect whether guards have been injured, ... of an extensive portfolio under the Intellectual Properties Agreements ... Lisa Pamintuan , President of New ...
(Date:6/19/2013)... to contribute to a very large and potentially record-setting ... University of Michigan ecologist and colleagues who released their ... Bay. , The Gulf forecast, one of two announced ... an oxygen-depleted, or hypoxic, region of between 7,286 and ... 10 largest on record. , The low end of ...
Breaking Biology News(10 mins):New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 2U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 3U-M researcher and colleagues predict possible record-setting Gulf of Mexico 'dead zone' 4
... Earth Observatory of Singapore (EOS) which aspires to ... addressing several of civilisation,s most serious environmental threats ... change aims to provide invaluable research and ... could potentially save hundreds of thousands of lives. ...
... determining ways to speed the return of residents to ... The first step is providing better, more accessible ... architects and others says Dr. Dave Tilotta, associate professor ... first part of a multi-phase study examining the resilience ...
... Hopkins engineer is trying to coax human stem cells ... could someday be used to replace damaged tissue in ... Sharon Gerecht, an assistant professor of chemical and molecular ... received a $150,000 two-year grant from the March of ...
Cached Biology News:The Earth Observatory of Singapore devoted to the study of earth sciences officially opens 2The Earth Observatory of Singapore devoted to the study of earth sciences officially opens 3Defying the disaster: Researcher explores resilient housing 2Researcher seeks to turn stem cells into blood vessels 2Researcher seeks to turn stem cells into blood vessels 3
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
The FlowTACS Apoptosis Detection Kit is designed specifically for in situdetection of apoptotic...
Biology Products: